Daily Roundup

Resmed Reports Strong Q3 Growth Across All Metrics

Resmed Inc. delivered solid third-quarter results, with net revenue climbing to $1.41 billion, up 6.7% year-over-year. The real standout was the bottom line—net income surged 20.1% to $418.4 million, translating to diluted earnings per share of $2.92. The company's sleep and breathing health products segment generated $1.26 billion in revenue, while its residential care software business contributed $155 million. With $1.01 billion in cash on hand and $95 million in dividends paid during the quarter, Resmed is in a strong financial position. Looking ahead, the company expects full-year revenue to land between $5.5 billion and $5.6 billion, with continued growth anticipated across both core segments.

Pioneer Credit Locks in Major Bank Partnership

Pioneer Credit Limited has inked a significant three-year agreement with one of Australia's four major banks, marking another milestone for the debt collection company. The deal came with immediate action—Pioneer completed its first portfolio acquisition under the arrangement, picking up approximately 17,000 customer accounts with a face value of $206 million for $14.4 million. Active servicing of those accounts kicks off in early February 2027. What makes this particularly notable is that Pioneer is now the only purchaser with agreements in place with each of Australia's four major banks, positioning the company as a key player in the sector. The company plans to remain disciplined in its approach, focusing on delivering appropriate outcomes for customers, banks, and shareholders alike.

Orthocell's U.S. Nerve Repair Product Hits New Heights

Orthocell Limited is riding momentum with its Remplir nerve repair product in the United States. October marked the strongest sales month since the product's launch, with the company moving 92 units and generating AU$279,000 in revenue—an impressive 84% jump from the average monthly sales of 50 units during the first quarter of fiscal 2027. The surge reflects growing surgeon adoption, increased repeat purchases, a broader network of actively selling distributor representatives, and expanded hospital access across key U.S. markets. The board remains confident in Remplir's significant market potential and the company's ability to translate expanding market access into sustained commercial success.

Emperor Energy Secures Drilling Rig for Major Well

Emperor Energy Ltd has executed a full contract with Valaris Limited to secure the VALARIS 107 jack-up drilling rig for the Judith-2 Appraisal Well. The rig will be available in April 2027 after completing current commitments in the offshore Gippsland Basin. Emperor has already paid $3.5 million upfront—$1.5 million in September when the term sheet was agreed, plus an additional $2.0 million upon executing the full contract. These payments are credited against the total drilling contract value, which runs at US$165,000 per day for a minimum 30-day duration. Additional payments will come due in 2027 before the rig mobilizes. The company's Drilling Environmental Plan received approval from NOPSEMA in late September, clearing another hurdle toward the planned drilling campaign.

Noxopharm Advances Clinical Pipeline and Secures Funding

Noxopharm Limited has been busy on multiple fronts. The clinical-stage biotech company is progressing its lead drug candidate, SOF-SKN, into an extension clinical study for cutaneous lupus erythematosus patients in Melbourne, while also reporting promising data from its immuno-oncology program. Research involving Noxopharm's technology was presented at the International Society for Respiratory Viruses conference, demonstrating potential in reducing vaccine-related inflammation markers.

On the funding side, Noxopharm successfully raised $1.5 million through a placement of new shares at $0.042 per share and will offer a Share Purchase Plan to eligible shareholders targeting up to $1.0 million. The company also negotiated early conversion of $3.78 million in Shareholder Convertible Notes. These funds will support the SOF-SKN extension study, Investigational New Drug-enabling activities for a Phase 2 trial, preclinical programs, and working capital needs. The capital raise came just as the company's trading suspension was lifted on the ASX following the announcement, allowing shares to resume quotation.